Since the exit of nucleic acids, pharmaceutical companies have entered the scene. Lianhua Qingwen made an academician the richest man, and ibuprofen made the boss of Hendy Pharmaceuticals earn 6 billion in 45 days.

Since the exit of nucleic acids, pharmaceutical companies have appeared. A Lianhua Qingwen made an academician the richest man, and an ibuprofen made the boss of Hendy Pharmaceuticals earn 6 billion in 45 days. But in fact, there are still people who are making a lot of money behind their backs, and they are making a lot of money. Let’s first look at a set of data. The net profit of in the first three quarters of this year was 16.05 billion yuan, a year-on-year increase of of 31918.64%; excluding non-net profit, it was 16.232 billion yuan, a year-on-year increase of 65616.92%. , is it that can’t even count the number of digits? Converted, that means net profit surged 319 times, and non-net profit after deducting it surged 656 times.

This giant is Jiu'an Medical, a company that produces medical devices products. It has caught up with the epidemic, and its revenue and profits have skyrocketed. The company's stock has become a " demon stock ". So, how did Jiu'an Medical make its fortune? How did you seize the bonus of the epidemic? We have to start with its founder.

The founder of Jiu'an Medical is named Liu Yi. He was born in an ordinary family in Tianjin. He did very well in studies since he was a child. He was later admitted to Tianjin University to major in analytical instruments. After graduation, he was assigned to work at the Shanghai No. 3 Analytical Instrument Factory, winning the "iron rice bowl" that everyone envied at the time. If this trajectory continues, Liu Yi will only need to endure it slowly until retirement, and live a worry-free life.

However, Liu Yi is not a person who is content with the status quo. In just one year, he smashed his iron rice bowl and quit. A man went to Guangdong to find a job and joined a company selling health care products named Sun God. This company was popular all over the country at that time, and its advertisements could be seen everywhere. Liu Yi felt like a fish in water here, and later became a manager and accumulated a lot of experience.

However, entrepreneurs are often trouble-makers. How can they be willing to be subordinate to others and keep working for others? So, in 1995, Liu Yi roped in a few classmates to go it alone and founded Jiu'an Medical, whose product was the electronic blood pressure monitor . The start was very smooth, with more than 1,000 units sold within one month of its launch, which was a good start. However, since then, the performance has been hovering around 10 million, which has caused them a headache. Therefore, they had to open up the international market, but they did not expect that the space would be so huge.

By opening up the international market, Jiu'an Medical's shipments have also been rising steadily, entering the forefront of the world. At the same time, Jiu'an Medical has expanded its products to include household medical devices such as blood glucose meters and forehead thermometers. After that, it also caught up with Apple, and Xiaomi , and became very popular.

In 2010, Jiuan Medical was listed on the Shenzhen Stock Exchange, becoming the first domestic listed company in the sphygmomanometer industry. is generally "the first in the industry" and is highly sought after by capital, but unexpectedly, Jiu'an Medical was disliked. The stock price was always only a few yuan, and it was once evaluated as a junk stock. Why is

like this? The reason is still poor performance. Revenue growth is slow. In 2010, revenue was 299 million yuan. In the following years, it hovered within 500 million yuan, and it only exceeded 700 million yuan in 2019. The net profit is even worse. From 2010 to 2019, the net profit lost 174 million yuan, not making a penny, and losing nearly 200 million yuan. No wonder capital looks down on it.

Making money may really depend on luck. When you are lucky, it is difficult not to make money. No, the three-year epidemic has completely transformed Jiu'an Medical. Not only has it made up for the losses in the 10 years since its listing, it has also made huge profits. From 2020 to the third quarter of 2022, Jiuan Medical’s total net profit reached 17.205 billion yuan. I have been in business for 27 years, and I have only made money in these three years.

It is understood that after the domestic epidemic in 2020, Jiu'an Medical seized the demand for temperature measurement, sold a large number of forehead thermometers, and made a small profit. Later, as the epidemic spread around the world, Jiu'an Medical sold the forehead thermometers overseas. However, what really made Jiu'an Medical's performance soar was not the forehead thermometer, but the antigen kit.

We all know that foreign countries opened up earlier than us, and they had a huge demand for antigen testing very early on.Jiu'an Medical's self-developed antigen kit received FDA certification in November last year and officially entered the U.S. market. It also won half of the U.S. government's procurement contracts, amounting to US$1.27 billion.

This was an incredible moment, Jiu’an Medical’s performance took off like a rocket. Jiu'an Medical's revenue in the first three quarters of this year reached 24.589 billion yuan, a surge of 30 times. Since entered the US market, Jiu'an Medical's market value has soared from less than 3 billion to over 39 billion in five months, becoming a "demon stock". According to founder Liu Yi’s 22.88% shareholding ratio, his net worth is close to 9 billion, which undoubtedly directly propels him to the throne of Tianjin’s richest man.

Nowadays, with the liberalization of the country, antigens have become "hard to find in a box" and the demand is very huge. This is a larger market than overseas. As a leading company in the production of antigen reagents, Jiu'an Medical has undoubtedly ushered in another opportunity, which means that the revenue and profits in the fourth quarter will increase sharply.

In the past three years, the epidemic has made most people suffer, while also enriching a small number of people. went from the boss of Mindray Medical becoming the richest man in Singapore, to Sinovac Biotech making a net profit of 100 billion a year, to Lianhua Qingwen, Hengdi Pharmaceuticals, and Jiu'an Medical. However, the epidemic will eventually pass, and antigens are only short-term dividends. For companies like Jiu'an Medical, they still have to find ways to expand more businesses and improve their core competitiveness. Otherwise, after this trend, they are likely to be knocked back to their original shape.